Rep. Porter Honored For Work on Budget

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

WASHINGTON--Representative John Edward Porter of Illinois has received an American Academy of Otolaryngology--Head and Neck Surgery, Inc. award for "superb legislative leadership for medical research."

WASHINGTON--Representative John Edward Porter of Illinois hasreceived an American Academy of Otolaryngology--Head and NeckSurgery, Inc. award for "superb legislative leadership formedical research."

Rep. Porter, in his first year as chairman of the House of Representative'sSubcommittee on Labor-HHS-Education and Other Related Agencies,succeeded in extricating medical research funding from the overallbudget battle, thus assuring continuation of medical researchat medical centers and universities throughout the country.

In presenting the award, Robert J. Ruben, MD, professor of pediatrics,Albert Einstein College of Medicine of the Yeshiva Universityand Montefiore Medical Center, New York City, said that Rep. Porter'sleadership "allows vital research work . . . to go forwarduninterrupted . . . not only in our field, but also in the fieldsof cancer, heart disease, and lung disease--indeed in all healthareas of profound interest to the American people, and peopleworldwide."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content